The safety and effectiveness of pegfilgrastim to reduce cancer chemotherapy-induced febrile neutropenia in real-world practice in Japan: a post-marketing surveillance study
This survey confirmed that both primary and secondary prophylaxis using pegfilgrastim reduced FN in the real-world setting. No new safety concerns were identified. This survey was retrospectively registered on 26 April 2024 in the University Hospital Medical Information Network Clinical Trial Registry (UMIN000054267).
Authors
- Nobuhiro Shibata (ORCID: https://orcid.org/0000-0001-8647-5098)
- T Yasukawa (ORCID: https://orcid.org/0009-0000-8960-158X)
- Shigehira Saji (ORCID: https://orcid.org/0000-0002-6732-8030)
- Manabu Iwabuchi
- Hiroshi Kuwazawa
Institutions
- Kansai Medical University (JP)
- Fukushima Medical University (JP)
- Kyowa Kirin (Japan) (JP)
Publication Details
- Journal
- Supportive Care in Cancer
- Published
- 2025-11-22
- DOI
- https://doi.org/10.1007/s00520-025-10042-6
- Primary Topic
- Neutropenia and Cancer Infections
- Type
- article
- Field-Weighted Citation Impact
- 0.00